ArticleWorld journal of diabetes2024

Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome.

Gu-Lao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.